Global HIV drug resistance surveillance.
The transmission of drug-resistant strains of human immunodeficiency virus (HIV) is of increasing concern in countries where antiretroviral therapy is widely used and does not spare countries where highly effective antiretroviral therapy has been recently introduced. The global HIV drug resistance surveillance programme will track the drug susceptibility in a rapidly moving epidemic, to provide information necessary to develop effective treatment strategies, to support and complement programmes aimed at increasing HIV therapy availability, and to assist in targeting and complementing drug resistance prevention strategies.
De Felici
Annapaola
A
Communicable Diseases Surveillance and Response Department, World Health Organization of Geneva, Switzerland.
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005544:Forecasting; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D015994:Incidence; D008297:Male; D008826:Microbial Sensitivity Tests; D018570:Risk Assessment; D012720:Severity of Illness Index; D014944:World Health Organization
D019380:Anti-HIV Agents